Skip to NavigationSkip to content


Johns Hopkins researchers to study psilocybin as a treatment for anorexia in Phase 1 trial

Scientists at Johns Hopkins University are exploring psilocybin as a potential treatment for chronic anorexia nervosa.

Researchers at Johns Hopkins Psychedelic Research Unit are launching a Phase 1 trial into the safety and efficacy of ‘magic mushroom’ ingredient psilocybin as a treatment for anorexia nervosa.

Anorexia nervosa has the highest rate of mortality of any psychiatric disorder. In 2017, a study found the psychedelic Ayahuasca showed promise as a treatment for the condition.

Illegal psilocybin shows promise in treatment of depression

A double-blind study of psilocybin, the hallucinogenic drug chemical found in ‘magic mushrooms’,  has been found to have substantial mental health benefits in those suffering from life-threatening cancer diagnosis. Patients were found to have relief from symptoms of cancer-related anxiety of depression for up to six months after being treaetd with a large dose of the drug.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches